Marker Therapeutics announces 2023 annual meeting voting results; all director nominees elected

Proposal No. 2 : Approval, on an advisory basis, of the compensation of the Company’s named executive officers. The votes were cast as follows: Votes For Votes Against Abstained Advisory approval of named executive officer compensation 2,347,263 321,791 27,721 Broker Non-Votes: 3,193,097.

Proposal No. 3 : Indication, on an advisory basis, of the preferred frequency of future shareholder advisory votes on the compensation of the Company’s named executive officers. The votes were cast as follows: One Year Two Years Three Years Abstained Advisory indication of preferred frequency of future shareholder advisory votes on named executive officer compensation 2,535,976 25,098 102,082 33,619 Broker Non-Votes: 3,193,097.

Proposal No. 1 : Election of five nominees to serve as directors until the 2023 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld David Eansor 2,488,644 208,131 Steven Elms 2,500,415 196,360 John Wilson 2,473,599 223,176 Juan Vera 2,499,068 197,707 Katharine Knobil 2,495,539 201,236 Broker Non-Votes: 3,193,097.

Proposal No. 4 : Ratification of the selection of Marcum LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Marcum LLP 5,760,786 109,958 19,128 Broker Non-Votes: 0.